Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
16 hedge funds and large institutions have $86.2M invested in Evofem Biosciences, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
6% more capital invested
Capital invested by funds: $81.4M → $86.2M (+$4.76M)
0% more funds holding
Funds holding: 16 → 16 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.64M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$211K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$145K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.5K |
| 5 |
BlackRock
New York
|
+$495 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$248K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$23.3K |
| 3 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$17K |
| 4 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
-$16.7K |
| 5 |
Morgan Stanley
New York
|
-$8.8K |
EVFM Hedge Fund Activity: Q4 2018 in Review
16 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2018, worth a combined $86.2M — up 5.8% from $81.4M a quarter earlier.
Fund positioning in EVFM was balanced in Q4 2018: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Heartland Advisors, adding an estimated $1.64M. The largest seller was Millennium Management, cutting an estimated $248K.
- 16 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $86.2M of Evofem Biosciences, Inc. Common Stock stock for Q4 2018, up 5.8% quarter-over-quarter.
- 1 fund opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2018 and 1 closed out, a net change of 0 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2018 was Heartland Advisors, an estimated $1.64M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q4 2018 was Millennium Management, an estimated $248K sold.
Based on aggregated 13F filings for Q4 2018.